Literature DB >> 16481646

Autoimmunity and immunotherapy for cancer.

Henry Koon, Michael Atkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16481646     DOI： 10.1056/NEJMe058307

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Authors:  Byram W Bridle; Lan Chen; Chantal G Lemay; Jean-Simon Diallo; Jonathan Pol; Andrew Nguyen; Alfredo Capretta; Rongqiao He; Jonathan L Bramson; John C Bell; Brian D Lichty; Yonghong Wan
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

Review 2.  Type17 T-cells in central nervous system autoimmunity and tumors.

Authors:  Hideho Okada; Samia J Khoury
Journal:  J Clin Immunol       Date:  2012-03-28       Impact factor: 8.317

3.  Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.

Authors:  José-Alberto Palma; Salvador Martín-Algarra
Journal:  J Neurooncol       Date:  2009-03-06       Impact factor: 4.130

4.  Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.

Authors:  Jason M Zimmerer; Gregory B Lesinski; Amy S Ruppert; Michael D Radmacher; Carl Noble; Kari Kendra; Michael J Walker; William E Carson
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

5.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors:  Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

Review 6.  Biomarkers for immunotherapy in genitourinary malignancies.

Authors:  Susan F Slovin
Journal:  Urol Oncol       Date:  2015-03-16       Impact factor: 3.498

7.  Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.

Authors:  Stefano M Santini; Caterina Lapenta; Simona Donati; Francesca Spadaro; Filippo Belardelli; Maria Ferrantini
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

8.  Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry.

Authors:  Nadera J Sweiss; Wei Zhang; Beverly S Franek; Silvia N Kariuki; David R Moller; Karen C Patterson; Peggy Bennett; Lakshmi R Girijala; Vaisak Nair; Robert P Baughman; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

9.  Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.

Authors:  Biagio Ricciuti; Abdul Rafeh Naqash; Jarushka Naidoo; Kartik Sehgal; Adam Miller; Kenneth Kehl; Deepti Venkatraman; Jacob Sands; Giuseppe Lamberti; Gonzalo Recondo; Jiajia Zhang; Shravanti Macherla; Sameer Baig; Paul Walker; Deepa Rangachari; Justin F Gainor; Daniel B Costa; Naiyer Rizvi; Lynette M Sholl; Mizuki Nishino; Brian Henick; Anna F Farago; Mark M Awad
Journal:  JTO Clin Res Rep       Date:  2020-07-15

Review 10.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Erika Vacchelli; Ilio Vitale; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fučíková; Isabelle Cremer; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.